Optimizing Immunotherapy: Roswell Park Identifies Promising Biomarker of Response to Checkpoint Inhibitors
June 25, 2020
June 25, 2020
BUFFALO, New York, June 25 -- The Roswell Park Comprehensive Cancer Center issued the following news release on June 24:
While immune checkpoint inhibitors have driven dramatic improvements in survival for patients with many cancer types over the last decade, there is still much to be learned about the most effective use of these immunotherapies. Particularly in patients with non-small cell lung cancer, or NSCLC, responses to this class of drugs are widely varied, and the need for a . . .
While immune checkpoint inhibitors have driven dramatic improvements in survival for patients with many cancer types over the last decade, there is still much to be learned about the most effective use of these immunotherapies. Particularly in patients with non-small cell lung cancer, or NSCLC, responses to this class of drugs are widely varied, and the need for a . . .